Pharmaceutical Benefits Advisory Committee review of pneumococcal vaccines on the National Immunisation Program for older adults

Last updated 6 August 2019


Date: 27 June 2019

The RACGP provided input on the recent PBAC review of pneumococcal vaccines in older adults. Emphasis was placed on the importance of a sound evidence-base for the removal of any vaccine from the NIP.

The RACGP response covers the following:

  1. Vaccine effectiveness and cost effectiveness against invasive pneumococcal disease and community-acquired pneumonia
  2. The impact of removing a vaccine from the National Immunisation Program.